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Multicentre phase II pharmacological evaluation of rhizoxin
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Summary Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule 
assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety o f  human tumour cell lines 
and xenograft models. Phase I evaluation found a maximum tolerated rhizoxin dose of 2.6 m g m " 2, with 
reversible, but dose-limiting, mucositis, leucopenia and diarrhoea. Clinical trials were then initiated by the 
EORTC ECSG in melanoma, breast, head and neck, and non-small-cell lung cancers with the recommended 
phase II rhizoxin dose of 2 mg m ~ 2. Pharmacological studies were instituted with the phase II trials to 
complement the limited pharmacokinetic data available from the phase I trial. Blood samples were obtained 
from 69 of 103 eligible patients enrolled in phase II rhizoxin studies, and these were evaluable for 
pharmacokinetic analysis in 36 patients. Plasma rhizoxin concentrations were determined by high-performance 
liquid chromatography (HPLC), and post-distribution pharmacokinetic parameters were estimated by a one- 
compartment model. Rhizoxin was rapidly eliminated from plasma, with a median systemic clearance of 
8.4 1 min m 2 and an elimination half-life o f  10.4 min. Rhizoxin area under the concentration- time curve 
(AUC) was higher in patients obtaining a partial response or stable disease than in those with progressive 
disease (median 314 vs 222 ng m l“ 1 min; jP =  0.03). A s predicted from previous studies, haematological and 
gastrointestinal toxicity was observed, but could not be shown to be related to rhizoxin AUC. This study 
demonstrated the rapid and variable elimination o f  rhizoxin from the systemic circulation. The presence of 
pharmacodynamic relationships and the low level of systemic toxicity suggest that future trials of rhizoxin with 
alternative dosage or treatment schedules are warranted.
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Rhizoxin is a 16-membered macroc lactone that has 
displayed cytotoxicity against a variety of human tumour cell 
lines and activity in xenograft models (Hendriks et al., 1992). 
The drug binds to tubulin at the vinblastine/maytansine site 
and inhibits microtubule assembly, inducing a cell cycle block
at G2-M (Tsuruo et al., 1986; Sullivan et al., 1992). Preclinical
evaluation haematopoietic, gastrointestinal and
injection-site toxicity (Hendriks et a l 1992). A phase I trial 
of rhizoxin administered as a 5 min infusion found a 
maximum tolerated dose of 2.6 mg m 2 and a recommended
phase 11 of 2.0 mg m (Bissett et a/,,
limiting, with grade 3--4 
s receiving 2.6 mg m 2. An
in two patients with
Myelosuppression was 
neutropenia in 7/8 pi 
objective response was
advanced local recurrence of breast cancer, including 
patients with the highest area under the plasma concentra­
tion-time curve (AUC). Rhizoxin was only detectable in 
plasma from patients receiving ^2 mg nr 2 in this study. 
Pharmacodynamic analysis was not possible owing to the 
small number of evaluable pharmacokinetic studies. The 4- 
fold range of systemic clearance observed in the limited 
number of patients studied provided further impetus for this 
phase II pharmacokinetic/pharmacodynamic evaluation.
Materials and methods
Patients were accrued for pharmacological evaluation from 
EORTC ECSG phase II trials of rhizoxin in melanoma,
breast, head and neck, and non-small-cell lung (NSCLC)
» •
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cancers (Kaplan et al., 1996; Verweij et al., 1996; Hanauske 
et al., 1996). Participation in the pharmacological studies was
II trials.encouraged, but not mandatory in the 
Rhizoxin 1.5 -2.0 mg in '2 was administered intravenously 
(i.v.) over 5 min (actual administration time 1-10 min). 
Toxicity was graded by the NCI common toxicity criteria
overall anti-tumour 
response was evaluated for each patient after two courses
after each course of therapy.
o f ipy and graded as a response, partial
response, stable disease/no change or progressive 
The percentage change in absolute neutrophil count or white 
blood cell count for each individual course was calculated as:
(pretreatment, count—
lowest measured count/pretreatment count) * 100
Rhizoxin pharmacokinetic studies were performed with the 
first administered dose. Blood samples (5 ml) were obtained 
in heparinised tubes before therapy and 5, 10, 20 and 30 min 
after infusion. The samples were then centrifuged (1000 g) for 
5 min and plasma samples stored at — 20°C until transport in 
dry ice by express courier to the central drug analysis centre. 
Samples were then maintained at — 20°C until analysis.
As blood samples are processed with a varying degree of 
urgency at individual institutions, the ex vivo degradation of 
rhizoxin was assessed in the laboratory. Rhizoxin 50 ng ml 1 
was added to aliquots of fresh human whole blood and 
plasma and incubated at 26 C for 0, 0.5, 1, 2 and 3 h. Whole 
blood samples were then centrifuged (1000#) for 5 min and 
plasma samples stored at — 20‘C until analysis.
Rhizoxin plasma concentrations were determined using a 
previously described isocratic HPLC assay with ultraviolet 
detection (Graham et al., 1992). Rhizoxin was extracted from 
plasma by solid-phase extraction and separated on a C6 
reverse-phase analytical column by HPLC with a mobile
phase of 45% acetonitrile in 0.01 m phosphate buffer, pH 7, 
at a flow rate of 1 ml min"1. Rhizoxin was detected as a 
single peak (retention time 4 min) by ultraviolet detection at 
310 nm, The interassay coefficient of variation at 10 ng ml"1 
and 500 ng ml"1 was <10%. The limit of detection was 
1 ng ml-1.
A population pharmacokinetic model was initially 
developed with data from the Glasgow phase I trial (Bissett 
et al., 1992) and the current phase II population. The 
computer package NONMEM was used to estimate mean 
pharmacokinetic parameter values and their associated 
standard deviation in the population (Boeckman et al.). 
Estimates of the pharmacokinetic parameter values in the 
individual patient were obtained using patient plasma
concentrations in a Bayesian 
NONMEM).
(available in
The varn of the pharmacokinetic
parameter values in the population was modelled using an 
exponential structure, i.e. Pt- P  exp (%), where P, represents 
the parameter (clearance, volume, etc.) estimate of the <th
individual and P represents the value within the
population, il, represents the individual difference between P,
and P and r\ is assumed to be normally distributed with 
mean zero and variance co2.
The residual intrasubject variability was described using 
an additive and proportional model: C,, = C(/( 1 + ej(I) + i'.2lp 
where Q  represents the /th measured concentration in the 
/th individual and CtJ is the f th predicted concentration in 
the /th individual. The differences in measured and
lij and fi2 i>predicted concentrations are represented by /: 
which are assumed to be normally distributed with means 
zero and variances cr,2 and a22 respectively. Pharmacody­
namic analysis was restricted to patients with evaluable 
rhizoxin pharmacokinetics. Rhizoxin AUC was calculated 
as: AUC = dose/systemic clearance. The median value of 
rhizoxin AUC for each grade of toxic or therapeutic effect 
was compared using the Kruskal-Wallis (K~W) test or the 
Mann - Whitney (M --W) test as appropriate. Groups were 
merged as indicated to provide sufficient numbers for valid 
analysis.
Results
Blood sampling was performed in 69 of the 
patients enrolled in the four phase II rhizoxin studies (67%)
; Hanauske et al..(Kaplan et al., 1996; Verweij et al., 
1996). Of 18 centres involved in the II tr 14
in the pharmacological evaluation of rhizoxin,
Europe.
sampling was performed in 78% of patients enrolled from
(range 11 
t u m o u r
Accrual 
LC 2
plasma
samples
melanoma 19/26 (73%), head and 
breast 8/17 (47%).
Rhizoxin was detectable in the plasma of 53 patients. The
remaining patients were 
interfering plasma peak in
patients), no detectable plasma rhizoxin (live patients) 
early sampling
no
to acute toxicity patient).
Rhizoxin was detectable in the plasma of 70% of patients at
10 min after 25%) of patients at 20 min
infusion, and was detectable in only four patients at 30 min
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The time between sample collection and processing was
unlikely to detection of rhizoxin, as little
degradation (<10% of rhizoxin was observed ex vivo in 
human whole blood or plasma over 3 h.
Figure 1 shows that the rhizoxin plasma profile requires at 
least a two-compartment model to describe the data. When 
one- and two-compartment models were fitted to the data 
using NONMEM, the two-compartment model gave a better 
fit Of = 44 with 2 d.f., P < 0.001). However, there were 
insufficient data to estimate reliably the values for all four 
parameters in the model (volume of distribution, elimination 
constant and intracompartmental constants). The distribution 
phase was very rapid and complete by 10 min after the end of 
the infusion, so only the 5 min after infusion sample gave 
information about distribution parameters. To overcome this 
problem, all measured concentrations up to and including 
5 min after the end of the infusion was censored and a one- 
compartment model fitted to the remaining data from the 
seven phase I and 36 phase II patients. The parameter values 
and their associated errors estimated using this model are 
given in Table I.
Individual parameter estimates derived using the Bayesian 
algorithm implemented in NONMEM are summarised for all 
36 phase II patients and for each tumour type in Table II. No 
significant correlation was observed between patient age and 
rhizoxin AUC.
The median AUC was not the same for all tumour types 
(Table II; K -W , P = 0 .0 3). However, pairwise comparisons
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Figure 1 Concentration time profile o f  rhizoxin in 37 phase II 
patients with more than one detectable plasma sample.
Table I Population parameter estimates from a one-compartment
model NONM EM  analysis
B M M m t u i u w i i P l I M
h
Standard error o f
A.Vfc tI V
Clearance (1 min 1 m ‘) 
id2 clearance (% CV)
Volume of central
7.6
0.375 (61%) 
128.0
0.93
0.146
41.4
( 1  m'2)
or volume (% 
cr,2 (% CV)
rr22 (ng ml ')
0.395 (63%)
0.033 (18%) 
0.394
0.293
0.0153
0.0347
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Table II Median (and range) o f  individual parameter estimates for the 36 phase II patients and for each tumour type
-------— --------------- i ------------------------i h i —  -----------------------  ~~~~i u n — — — n -------------  i i m n - r ^ — ~ ~ — — r  '  ... ........... i n  i-------------- —  '  '  "  ~ r r i « n — ■ ■ ■ « P if  T i n n w i r i w n m » M » m i i m i  ........... ,i i t * m« p T T r mT mr r * - ~ t ^ — r - * ~ n — —— p— w— ^
*►......... t  Y * * >  I • * • • • ! • «  I t  M i t ' J i l t L l ' T . t J i  M ,  ( . 1 . 1  .  , i , A j *•  I*.  • I * *- i  •* * ' (  .
Clearance (1 min 1 m 2) 8.4 (1.3 16.3)
Volume (1 m 2) 
Half-life (min) 
AUC (ng ml 1 m in)
122 (27 156) 
10.4 (3.5 19.2) 
241 (115 1532)
Breast
8.8 (1.4 14.5) 
135 (28 156) 
10.5 (6.6-18.2) 
230 (1391422)
- f *  M A I .  • ; . «  ...................................... ............................................  I Q  I  É  ^ 9  *■* '  ■  f *  » I  ■  J « *
Head and neck fn =  9) Melanoma fn = 11) N S C L C  (n ~ 11)
6.4 (1.3-13.3)
122 (27-139)
11.9 (6.817.2) 
315 (150-1532)
10.8 (3.5-16.3) 
103 (85146) 
7.9 (3.6 19.2) 
148 (115414)
9.9 (6.4-16.0) 
126 (81-135) 
9.2 (3.5-14.7) 
203 (124-314)
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of the median AUC in each tumour type failed to identily 
significant differences when a rom corree was
applied to account for multiple testing.
As predie from the preclinieal and phase I studies,
toxicity from rhizoxin was primarily haematological (12% 
patients with grade III, 16% with grade IV neutropenia), 
gastrointestinal (5% patients with grade III stomatitis) and 
alopecia (complete in 23% of patients). In addition, pain at
the tumour site was observed in five patients (Verweij e t  c il., 
1996). No differences could be demonstrated in the median 
AUC at different toxicity grades for any of the measures of 
toxicity (Table III). No significant correlation could be 
demonstrated between the percentage reduction in WBC or 
the percentage in neutrophil count and rhizoxin AUC.
In the 36 patients evaluable for rhizoxin AUC, two 
patients achieved a partial response (PR), seven had stable 
disease (SD), and 23 had progressive disease (PD). Four
Figure 2 The relationship between rhizoxin A U C  and tumour 
response (M ann-W hitney  test, Z3 = 0.03). SD, stable disease; PR, 
partial response; PD, progressive disease. ’"Patients with very high 
rhizoxin AUC values,
patients were not evaluable in terms of tumour response. No 
complete responses were observed among the patients with 
evaluable rhizoxin pharmacokinetics. The nine cases with PR/ 
SD (six NSCLC, two head and neck and one melanoma) had 
a significantly higher median AUC (314 n g m l-1 min; range 
138-1532) than the 23 patients with PD (222 n gm l-'1 min; 
range 115- 1422) (Figure 2; M -W , P =  Q.03; 95% Cl -  16 to 
— 264). The small number of patients with PR/SD prohibited 
separate statistical analysis for each tumour type.
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Figure 3 Theoretical relationship between rhizoxin A U C and 
measures of haematological toxicity ( f t ,  grade I/II; □ ,  grade III/ 
IV) and tum our response (O)- Symbols represent data from the 
phase I (median 460ngm l 1 min) and phase M (median ALJC 
240ngm l 1 min) trials. The dashed lines for tum our response
two possible outcomes from further escalation of
systemic exposure; increased activity or plateau effect. There is 
currently not enough clinical data available to validate the in vivo 
presence o f  such relationships.
Table III Rhizoxin pharmacodynamics; comparison of median AUC and grade o f  toxicity
Toxicity
*
n
*— < u v . * *  i  *■ *t . ' j j , ■ ,  *  r t *
M  edititi
»  J .  k l «  r f l í J  > k«> 1 I -Lf J  ¿  <>,
A UC
^  . . j  j j i n u  . l ' i l .  ,  - , h h < J  V J  M  *  <*i' i  ' ■ * - '  1 ' ------* w . ‘  4 .  '1 Statistics—  ■ w . h ,  .  < f  I r r  . P . .  • ----------------------- A  fc .  1» h  ^ ± ê  ^ Æ ê k . A *
Alopecia Grade 0 7 6a* * * Amng ml 1 min K W, P  0.19
Grade 1 20 187
Grade 2 9 251
Asthenia Grade 0 25 252 ng ml 1 min M W, P  -  0.94; 95% Cl 64 to 102
Grade 1 3 11 TO?
Pain Grade 0 31 252 ng ml 1 min Insufficient data
Grade 2 4 5 174
Skin Grade 0 28 251 ng ml 1 min M~W, P =  0.98; 95% C l 86 to 102
Grade 1-3 8 223 •
Stomatitis Grade 0 22 253 ng ml 1 min M W, P  =  0.88; 95% Cl 58 to 102
Grade 1 3 14 223
WBC Grade 0 13 273 ng m l 1 min K W, />-(). 18
Grade 1 2 14 204
G rade 3 4 9 224
Neutrophils Grade 0 16 252 ng ml 1 min M W, /J = 0.88; 95% Cl 70 to 102
Grade 1 4 20 227
Platelets Grade 0 32 252 ng ml 1 min Insufficient data
Grade 1 2 4 223
Haemoglobin Grade 0 21 203 ng ml min M -W , P  = 0.68; 95% Cl -103 to 55
Grade 1 3 15 274
M -W , M ann-W hitney test; K W ,  Kruskal--Wallis test; CI, confidence interval for diflerence in median values.
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Discussion
Rhizoxin was rapidly eliminated from human plasma with a 
median clearance of 8.4 1 min 1 m ~ and elimination half-life 
of 10.4 min. These results are consistent with those observed 
in phase I pharmacokinetic analysis in which the median 
clearance was 4.2 1 min-1 n r 2 and elimination half-life was 
23.6 min. Rhizoxin was not detectable (< 1  ng ml"1) at 
30 min after injection in 93% of plasma samples. A high 
degree of interpatient variability in rhizoxin disposition was 
observed in this study. Systemic clearance ranged from 1.3 to 
16.3 1 miii 1 m 2 (CV = 61%), while volume of distribution 
was 2 7 - 1561m"2 (CV = 63%). A similar degree of varia-
bility was 
4.6 1 min 1
arance, 2.0
m 2.
in the phase I trial 
volume of distribution, 10.1 -55.4 1 nr'2)
(Bissett et til., 1992). In the current study, plasma rhizoxin
concentrations measured 5 min after infusion varied from
(<  1 ng ml ') * •' 1/1A "■* *"' 1to 40 ng ml an
10 ng ml '). Two patients had plasma rhizoxin concentra­
tions (and AUC estimates) which are considerably higher 
than in other patients (Figure 2). Both patients were from the 
same centre, which raises questions as to the reason for the 
high concentrations. However, they have been included in the 
analysis. As pharmacokinetic studies were only performed
course of rhizoxin, direct measurement ofwith
intrapatient variability in rhizoxin pharmacokinetics was not
The rapid elimination of rhizoxin makes pharmacokinetic 
analysis very difficult (McLeod et al., 1996). Traditional 
methods of both compartmental and non-compartmental 
pharmacokinetic analysis require 2 - 3  blood samples for each 
variable to be estimated and data collection over at least 
three half-lives to allow confident calculation of pharmaco­
kinetic parameters (Gibaldi and Perrier, 1982). Application of 
these ‘rules’ in the current study would have used 8 -1 2  blood 
samples over ^30 min, beyond the point at which rhizoxin 
was detectable in patient plasma. The difficulties in obtaining 
accurate estimates of pharmacokinetic parameters for a two- 
compartment model were such that only a one-compartment
could > L1 This required that early
concentration information be censored to give estimates of 
post-distribution drug elimination.
Although unidentified species were not in
chromatograms from patient plasma samples, the production 
of metabolite(s) via rhizoxin metabolism may contribute to 
the rapid elimination from plasma. The systemic clearance 
was greater than liver blood flow (approximately 1.5 1 min ')
o r
arance from plasma is
rhizoxin’s molecular target
in all subjects, implying that extrahepatic 
degradation was involved. Another potential mechanism of
to tubulin, 
ivan et al., 1990). Several 
blood and tissue components, including platelets, are rich in 
tubulin (Wild et a/., 1995). While binding to platelet tubulin 
is a theoretical source of variability in rhizoxin disposition, ex 
vivo incubation in whole blood or plasma for up to 3 h had 
little influence on rhizoxin plasma concentrations.
Rhizoxin AUC was significantly higher in patients with 
NSCLC (Table II). The mechanism for this alteration is not 
clear. The patients in the NSCLC study did not have prior 
systemic chemotherapy, ruling out the influence of platinum
and re u o n
clearance. As a considerable degree of overlap in systemic 
clearance was observed between the four tumour types, a
would t o evaluated to
is m
larger number of
that
NSCLC patients 
Although a
exposure of rhizoxin was observed in this study, there was
of va rii in
no evidence that rhizoxin AIJC was related to drug toxicity. 
One contributing factor is the low degree of toxicity in this 
study. Even among frequently occurring toxicitics, the 
majority of patients had grade I or II toxicity (Table III). 
Indeed, 44%> of patients had no neutropenia, 
contributing factor is the absence of extensive measurement
of haematological parameters, needed for accurate determi­
nation of nadir values. The lowest measured value was used
mine the % change in haematological parameters
from the
to
actual nadir
induced by rhizoxin therapy, which may
value. There is no easy solution to 
commonly encountered difficulty for pharmacodynamic 
analysis, as daily analysis of the blood profile is not 
practical. Bayesian modelling techniques for estimation of 
individual patient neutrophil profile is in an early stage of 
development and may provide a useful approach in the future
(Sonnichsen et al., 1994).
Rhizoxin plasma AUC was statistically higher in patients 
achieving a PR or SD than those with progressive disea.se
an 314 vs 222 ng nil.1 min, P = 0.03).
response group conti nine patients, with the majority 
having stabilisation of disease only, 
patients responding (PR + SD) was lower in 
pharmacological analysis than the whole study population 
(51% vs 28%) (Kaplan et a l 1996; Verweij et al., 1996; 
Hanauske et al., 
viewed with caution until confirmed by a larger clinical trial. 
Attention should also be paid to the choice of biological 
matrix for evaluating the therapeutic effect of highly potent 
drugs, such as rhizoxin. Variability in drug transport,
» and interaction with the cellular
should be
intracellular
target are but a few of the influencing events between 
measurement of a drug in plasma and pharmacological 
activity. As measurement of drug concentrations or degree of 
inhibition in microtubule assembly in the tumour is not 
feasible for the majority of patients, use of an alternative 
biological end point may be in order (Cassidy and McLeod, 
1995). Methods for determination of paclitaxel action on 
human platelet tubulin have been described following in vitro 
incubations and may be applicable for guiding the use of 
rhizoxin and other tubulin-interactive agents in future trials
(Rowinsky et al., 1988).
Another pharmacodynamic variable, which may be 
important for rhizoxin, is the amount of time that drug 
concentrations are maintained above a threshold concentra­
tion. This variable appears to be correlated with haemato­
logical toxicity in studies of other agents that interact with 
tubulin, such as paclitaxel (Gianni et al., 1995; Huizing et 
al., 1993). Relevant threshold concentrations are identified 
using individual patient pharmacokinetic parameters to
concentration time pr I n this
represents in vivo evidence of saturable biological processes, 
in which concentrations in excess of that requir
the a r do not contr to
pharmacological effect. Estimation of the time that rhizoxin 
plasma levels were above specific values was not determined 
in the current study, owing to the extensive assumptions in
rhizoxin pharmacokinetic pro that would have to be
made beyond 20 min after infusion. Future pharmacokinetic
analysis • . •more sensitive assay ( gas
chromatography with mass spectroscopy or enzyme-linked
inmmunosor assay) will 1 to ore the
importance of threshold concentrations to rhizoxin toxicity
and therapeutic activity.
The absence of a significant relationship between toxicity 
and rhizoxin systemic exposure in this study does not mean 
that one does not exist. The majority of patients in the
pharmacological study (73%) had grade 0 II haematological
7 m« m 2, whereas only 7% of patientst a
obtained an response. In the phase I study of 
2.6 rag ra 3 led to grade II1/IVcl
haematological toxicity in 87% of patients (Bissett et al., 
1992). These findings are consistent with the flat portion of
tumour response curve (e.g. Figure 3), where a 
relatively large increase in drug exposure does not translate 
into greater drug effect on the tumour. They also suggest that 
the in vivo concentration effect curve for rhizoxin toxicity is 
very steep. Indeed, assuming in vitro principles of pharmacol­
ogy hold true in humans, a concentration-effect curve, s 
as the theoretical example shown in Figure 3, may explain the
1948
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variability was observed for all pharmacokinetic parameters. 
Rhizoxin plasma AUC was higher in patients achieving a 
therapeutic response than in those with progressive disease.
clinical profile of rhizoxin. It is not known whether an 
increase in rhizoxin AUC will translate into greater anti­
tumour activity or if a plateau in response will occur. 
Therefore, future trials using higher rhizoxin dosage, methods 
for reducing dose-limiting side-effects, and/or alternative Acknowledgements
dosage schedules should be considered. Xhis study could not have been completed without the efforts of
In summary, rhizoxin is rapidly eliminated in humans, Ms te Velde and colleagues at the EORTC NDDO and the
with rhizoxin detectable in the plasma of only 7%  of patients participating physicians, nurses, data managers and laboratory
by 30 min after injection. A large degree of interpatient investigators of the EORTC ECSG and PA M M  groups.
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